Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by westcoast1000on Jun 18, 2023 5:40pm
310 Views
Post# 35502665

AA and mBC

AA and mBCIf I recall correctly, paxlitaxol is now generic, or at least under a sowewhat different patent regime than initially.

If that is the case, I would think there are not many obstacles to ONCY applying directly to the FDA for the pax'pelo combo for mBC for accelerated approval.

Hence that might be the most direct path to AA. Or we could apply for AA for pela on its own, which has virtually the same pfs results as Trodelvey, an ADC that is beign prasied on the NYT front page today. We have far less side effects than Tro and would likely cost a lot less also. 

With the panc results, the combo is with Tecentriq which Roche owns, so it seems that it would be harder if not impossible for us to apply to the FDA for AA without Roche.


<< Previous
Bullboard Posts
Next >>